Rozerem Related Published Studies
Well-designed clinical trials related to Rozerem (Ramelteon)
Ramelteon in the treatment of chronic insomnia: systematic review and
meta-analysis. [2012]
Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. [2011.10.01]
Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. [2011.10]
Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study. [2011.02]
Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. [2011.02]
A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. [2011.01]
Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study. [2010.12.15]
Ramelteon prior to a short evening nap impairs neurobehavioral performance for up to 12 hours after awakening. [2010.12.15]
Effects of the melatonin MT-1/MT-2 agonist ramelteon on daytime body temperature and sleep. [2010.06.01]
Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. [2010.06]
Effects of the melatonin MT-1/MT-2 agonist ramelteon on daytime body temperature and sleep. [2010.06]
Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis. [2009.05]
Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. [2009.04]
Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. [2009.03.01]
Ramelteon for the treatment of insomnia in menopausal women. [2009.03]
Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. [2009.03]
The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. [2009.03]
Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. [2009.03]
Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. [2009.02.15]
Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. [2009.02.15]
Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. [2008.10.15]
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect. [2008.07]
Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. [2007.09]
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. [2007.08.15]
Ramelteon for the treatment of insomnia. [2006.10]
Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. [2006.06]
Disposition Kinetics and Tolerance of Escalating Single Doses of Ramelteon, a High-Affinity MT1 and MT2 Melatonin Receptor Agonist Indicated for Treatment of Insomnia. [2006.02]
An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. [2006.01]
Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. [2005.03.01]
Well-designed clinical trials possibly related to Rozerem (Ramelteon)
Night-to-night variability of sleep latency significantly predicts the magnitude of subsequent change in sleep latency during placebo administration. [2011.06]
Night-to-night variability of sleep latency significantly predicts the magnitude
of subsequent change in sleep latency during placebo administration. [2011]
A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. [2010.05]
Other research related to Rozerem (Ramelteon)
Ramelteon for the treatment of insomnia in adults: a systematic review and
meta-analysis. [2014]
A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for
the treatment of insomnia and mood stability in patients with euthymic bipolar
disorder. [2013]
Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia. [2011.10]
Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia. [2011.10]
Treatment of delirium with ramelteon: initial experience in three patients. [2011.07]
Ramelteon and improved insomnia in alcohol-dependent patients: a case series. [2011.06.15]
Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice. [2011.02]
Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled,
crossover study in Japanese patients with chronic primary insomnia. [2011]
Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients
with schizophrenia. [2011]
Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a
randomized, double-blind, placebo-controlled study. [2011]
Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects
with chronic insomnia. [2011]
A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory
bipolar I disorder with manic symptoms and sleep disturbance. [2011]
A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. [2010.09.21]
Ramelteon attenuates age-associated hypertension and weight gain in spontaneously hypertensive rats. [2010.06]
Ramelteon prior to a short evening nap impairs neurobehavioral performance for up
to 12 hours after awakening. [2010]
Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. [2010]
Effects of ramelteon and triazolam in a mouse genetic model of early morning awakenings. [2009.11.03]
Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. [2009.09]
Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. [2009.08.15]
[A novel therapeutic drug: ramelteon] [2009.08]
[A novel therapeutic drug: ramelteon]. [2009.08]
Ramelteon: a review of its therapeutic potential in sleep disorders. [2009.06]
The effects of ramelteon in a first-night model of transient insomnia. [2009.01]
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. [2009.01]
Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. [2008.12.17]
Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat. [2008.10]
Ramelteon: a novel approach in the treatment of insomnia. [2008.09]
The effects of ramelteon in a first-night model of transient insomnia. [2008.08.06]
Effect of Ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. [2008.08]
Efficacy and clinical safety of ramelteon: an evidence-based review. [2008.08]
Ramelteon: A Novel Approach in the Treatment of Insomnia (CE) (September). [2008.07.23]
Ramelteon: a melatonin receptor agonist for the treatment of insomnia. [2008.01]
Sorafenib: in hepatocellular carcinoma. [2008]
Effect of Ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. [2007.12.01]
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. [2007.09]
A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. [2007.05]
Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. [2007.04]
Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. [2007.04]
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. [2007.02.10]
Ramelteon for insomnia in two youths with autistic disorder. [2006.10]
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. [2006.10]
Searching for new options for treating insomnia: are melatonin and ramelteon beneficial? [2006.07]
Ramelteon: a novel treatment for the treatment of insomnia. [2006.07]
Ramelteon: profile of a new sleep-promoting medication. [2006.04]
Ramelteon. [2005]
Other possibly related research studies
Pharmacologic management of insomnia: past, present, and future. [2006.12]
Practical considerations of new drugs: new choices for old problems. [2006.04]
Melatonin and sleep in aging population. [2005.12]
TAK-375 Takeda. [2005.01]
Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. [2004.11]
Therapeutic options for sleep-maintenance and sleep-onset insomnia. [2007.01]
Gateways to clinical trials. [2006.07]
Treating insomnia: Current and investigational pharmacological approaches. [2006.12]
Management of chronic insomnia in elderly persons. [2006.06]
Use of sleep-promoting medications in nursing home residents : risks versus benefits. [2006]
Potential therapeutic use of melatonin in migraine and other headache disorders. [2006.04]
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. [2005]
Gateways to clinical trials. [2005.10]
Gateways to clinical trials. [2004.12]
Gateways to clinical trials. [2004.11]
Gateways to clinical trials. [2004.07]
Gateways to clinical trials. [2003.11]
Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? [2007]
Greater incidence of depression with hypnotic use than with placebo. [2007.08.21]
Treatment options for insomnia. [2007.08.15]
New perspectives for the treatment of disorders of sleep and arousal. [2007.07]
Pharmacotherapy for insomnia. [2008.02]
Gateways to clinical trials. [2007.10]
Role of the melatonin system in the control of sleep: therapeutic implications. [2007]
|